Cardio-renal syndrome

This study tests a device called Aortix, a small pump placed in the main artery, to help remove excess fluid in people hospitalized with acute heart failure who are not responding well to diuretic medications. About 320 participants will be randomly assigned to receive either the…

This study tests a special pacemaker setting called SyncAV, used with left bundle branch area pacing, in people with heart failure and a heart block. The goal is to see if this setting can improve the heart's electrical timing and pumping strength. About 50 adults who already nee…

This study tests a device that uses radiofrequency energy to treat high blood pressure in the lungs (pulmonary hypertension) in people with heart failure. The goal is to see if it can reduce serious heart events like hospitalizations or death. About 750 adults with stable heart f…

This Phase 3 trial is testing whether a combination of two drugs, balcinrenone and dapagliflozin, works better than dapagliflozin alone to prevent heart failure events and cardiovascular death. About 4,800 adults with heart failure and moderate-to-severe kidney impairment who rec…

This study tests whether empagliflozin, a diabetes drug, can prevent death, new dialysis, or lasting kidney damage in people with cardiorenal syndrome type 1—a condition where heart failure suddenly worsens kidney function. About 200 hospitalized adults will receive either empagl…

This study tests a device that filters out overactive immune cells from the blood to reduce inflammation in patients with severe heart failure and worsening kidney function. Twenty ICU patients will receive 4-hour treatments daily for up to 6 days. The goal is to see if it safely…

This study looks at whether a procedure to repair a leaky tricuspid heart valve can improve kidney function, reduce swelling, and boost physical activity in older adults. Researchers will follow 100 participants for changes in kidney health, walking ability, and daily function. T…

This study looks at whether a personalized home exercise program can improve heart and kidney function in adults aged 18-75 who have both chronic heart failure and kidney problems (cardiorenal syndrome). Sixty participants will either receive standard medication alone or medicati…

This phase 3 trial tests whether the drug dapagliflozin (Farxiga) can reduce deaths and heart or kidney problems in people leaving the intensive care unit (ICU). About 600 adults who needed a breathing machine or blood pressure support will take either the drug or a placebo daily…

This study is testing a small device called the MiniLung petite kit, which helps oxygenate blood and remove carbon dioxide in newborns and children weighing 2 to 8 kilograms who have severe breathing or heart failure. The device works with a console to temporarily take over the w…

This study tests a home-based cardiac rehabilitation program delivered through a custom mobile app for people with heart failure. Participants use the app for education, mindfulness, and physical activity guidance, plus periodic video calls with an exercise physiologist. The goal…

This study looks at whether two proteins released by a struggling heart can be detected in the blood during acute heart failure. Researchers will measure these proteins in about 500 adults—some with stable or worsening heart failure and some healthy—to see if higher levels relate…

Researchers at the University of Calgary are testing a new, non-invasive way to assess heart function using a handgrip exercise. The study involves 100 adults, half with heart failure and half without. Participants squeeze a device with maximum force for two minutes while sensors…

This study looks at whether certain proteins in the blood can predict if someone with chronic heart failure will develop kidney problems (cardiorenal syndrome). Researchers will measure these proteins in 150 adults with heart failure and follow them for one year. The goal is to f…

This study is a large registry that will collect health information from up to 60,000 people with both heart and kidney disease. The goal is to better understand how these conditions interact and to find ways to predict and improve patient outcomes. No new treatments or procedure…

This study follows 100 adults who needed ECMO support for severe heart or lung failure. Researchers will track muscle size, strength, and quality of life over time to understand why some patients develop lasting weakness. No new treatments are being tested; the goal is to gather …